AL-15469A for the Treatment of Bacterial Conjunctivitis

This study is ongoing, but not recruiting participants.

Sponsored by:	Alcon Research
Information provided by:	Alcon Research
ClinicalTrials.gov Identifier:	NCT00331916

Purpose

The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.

Condition	Intervention	Phase
Bacterial Conjunctivitis	Drug: quinolone	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	AL-15469A for the Treatment of Bacterial Conjunctivitis

Further study details as provided by Alcon Research:

Primary Outcome Measures:

Secondary Outcome Measures:

Estimated Enrollment:	600
Study Start Date:	November 2005

Eligibility

Criteria

Inclusion Criteria:

Exclusion Criteria:

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00331916

Locations

United States, Texas
US
Fort Worth, Texas, United States, 76134

Sponsors and Collaborators

Alcon Research

Investigators

Study Director:

Stella Robertson, Ph.D.

Study Director

More Information

Study ID Numbers:	C-04-38
Study First Received:	May 30, 2006
Last Updated:	September 10, 2007
ClinicalTrials.gov Identifier:	NCT00331916
Health Authority:	United States: Food and Drug Administration

Study placed in the following topic categories:

Bacterial Infections
Eye Infections, Bacterial
Conjunctivitis, Bacterial
Eye Diseases

Eye Infections
Conjunctivitis
Conjunctival Diseases

Additional relevant MeSH terms:

Infection

ClinicalTrials.gov processed this record on January 15, 2009